The need to tailor the omission of axillary lymph node dissection to patients with good prognosis and sentinel node micro-metastases.

Date publication

septembre 2022

Journal

Cancer medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr COUTANT Charles

Tous les auteurs :
Houvenaeghel G, de Nonneville A, Chopin N, Classe JM, Mazouni C, Chauvet MP, Reyal F, Tunon de Lara C, Jouve E, Rouzier R, Daraï E, Gimbergues P, Coutant C, Azuar AS, Villet R, Crochet P, Rua S, Bannier M, Cohen M, Boher JM

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36127853

Résumé

Results of IBCSG-23-01-trial which included breast cancer patients with involved sentinel nodes (SN) by isolated-tumor-cells or micro-metastases supported the non-inferiority of completion axillary-lymph-node-dissection (cALND) omission. However, current data are considered insufficient to avoid cALND for all patients with SN-micro-metastases.

Mots clés

adjusted Kaplan-Meier estimator, axillary lymph node dissection, breast cancer, micro-metastasis, sentinel node

Référence

Cancer Med. 2022 09 20;: